A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade

Anaesthesia

Volumn 70, Issue 12, 2015, Pages 1441-1452

  Abad Gurumeta, A ^a   Ripolles Melchor J ^b   Casans Frances R ^c   Espinosa, A ^d   Martinez Hurtado E ^b   Fernandez Perez C ^b   Ramirez J M ^e   Lopez Timoneda F ^b   Calvo Vecino, J M ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPYRRONIUM BROMIDE; NEOSTIGMINE; ROCURONIUM; SUGAMMADEX; VECURONIUM; GAMMA CYCLODEXTRIN DERIVATIVE;

HUMAN; HYPOXIA; NEUROMUSCULAR BLOCKING; OXYGEN DESATURATION; PARALYSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT OBSTRUCTION; WEAKNESS; COMPARATIVE STUDY; POSTOPERATIVE NAUSEA AND VOMITING;

GAMMA-CYCLODEXTRINS; HUMANS; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; POSTOPERATIVE NAUSEA AND VOMITING;

EID: 84946833112     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/anae.13277     Document Type: Review

References (55)

1. Bom A, Bradley M, Cameron K, et al., A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angewandte Chemie 2002; 41: 266-70.
2. Epemolu O, Bom A,. The concept behind sugammadex. Revista Española de Anestesiología y Reanimaticiõn 2014; 61: 272-6.
3. Abrishami A, Ho J, Wong J, et al., Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database of Systematic Reviews 2009; 4: CD007362.
4. Eikermann M, Groeben H, Hüsing J, Peters J,. Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade. Anesthesiology 2003; 98: 1333-7.
5. Eikermann M, Blobner M, Groeben H, et al., Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. Anesthesia and Analgesia 2006; 102: 937-42.
6. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al., Intermediate acting nondepolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. British Medical Journal 2012; 345: e6329.
7. Murphy GS, Szokol JW, Marymont JH, et al., Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesthesia and Analgesia 2008; 107: 130-7.
8. Murphy GS, Szokol JW, Marymont JH, et al., Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology 2008; 109: 389-98.
9. Murphy GS, Szokol JW, Avram MJ, et al., Postoperative residual neuromuscular blockade is associated with impaired clinical recovery. Anesthesia and Analgesia 2013; 117: 133-41.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 2009; 151: 264-9.
11. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org (accessed 01/09/2015).
12. Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J,. The thresholds for statistical and clinical significance-a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Medical Research Methodology 2014; 14: 34.
13. Moher D, Shamseer L, Clarke M, et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015; 4: 1.
14. Higgins J, Altman D, Gøtzsche P, et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal 2011; 343: d592815.
15. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. http://tech.cochrane.org/revman/download (accessed 01/09/2015).
16. Viechtbauer W,. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 2010; 36: 1-48.
17. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2015. www.R-project.org/(accessed15/06/2015).
18. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clinical Trials 1986; 7: 177-88.
19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. British Medical Journal 2003; 327: 557.
20. Brok J, Thorlund K, Wetterslev J, Gluud C,. Apparently conclusive meta-analyses may be inconclusive-Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009; 38: 287-98.
21. Thorlund K, Engstrøm J, Wetterslev J, et al., User Manual for Trial Sequential Analysis (TSA). Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2011. www.ctu.dk/tsa/files/tsa-manual.pdf. TSA Software: www.ctu.dk/tsa/downloads.aspx (accessed 01/09/2015).
22. Wetterslev J, Thorlund K, Brok J, Gluud C,. Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008; 61: 64-75.
23. Strassburger K, Bretz F,. Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni-based closed tests. Statistics in Medicine 2008; 27: 4914-27.
24. Jakobsen JC, Wetterslev J, Winkel P, et al., Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014; 14: 120.
25. Brok J, Thorlund K, Gluud C, Wetterslev J,. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008; 61: 763-9.
26. Thorlund K, Devereaux PJ, Wetterslev J, et al., Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? International Journal of Epidemiology 2009; 38: 276-86.
27. Neumann I, Pantoja T, Penaloza B, et al., The GRADE system: a change in the way of assessing the quality of evidence and the strength of recommendations. Revista Medica de Chile 2014; 142: 630-5.
28. Flockton EA, Mastronardi P, Hunter JM, et al., Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. British Journal of Anaesthesia 2008; 100: 622-30.
29. Jones RK, Caldwell JE, Brull SJ, Soto RG,. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109: 816-24.
30. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gõmez JA,. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia 2010; 110: 64-73.
31. Lemmens JM, El-Orbany MI, Berry J, Morte JB, Martin G,. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiology 2010; 10: 15.
32. Schaller SJ, Fink H, Ulm K, Blobner M,. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology 2010; 113: 1-7.
33. Blobner M, Eriksson LI, Scholz J, et al., Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology 2010; 27: 874-81.
34. Illman HL, Laurila P, Antila H, et al., The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring. Anesthesia and Analgesia 2011; 112: 63-8.
35. Sabo D, Jones RK, Berry J, et al., Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium-induced blockade in patients undergoing abdominal surgery. Journal of Anesthesia and Clinical Research 2011; 2: 140.
36. Adamus M, Hrabalek L, Wanek T, et al., Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia 2011; 25: 716-20.
37. Gaszynski T, Szewczyk T, Gaszynski W,. Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia 2012; 108: 236-9.
38. Geldner G, Niskanen M, Laurila P, et al., A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia 2012; 67: 991-8.
39. Mekawy N, Fouad Ali EA,. Improved recovery profiles in sinonasal surgery. Sugammadex: does it have a role? Egyptian Journal of Anaesthesia 2012; 28: 175-8.
40. Woo T, Kim KS, Shim YH, et al., Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiology 2013; 65: 501-7.
41. Carron M, Veronese S, Foletto M, Ori C,. Sugammadex allows fast-track bariatric surgery. Obesity Surgery 2013; 23: 1558-63.
42. Castro DS, Leão P, Borges S, et al., Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy and Percutaneous Techniques 2014; 24: 420-3.
43. Wu X, Oerding H, Liu J, et al., Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology 2014; 12: 14-53.
44. Koyuncu O, Turhanoglu S, Ozbakis Akkurt C, et al., Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia 2015; 27: 51-6.
45. Paton F, Paulden M, Chambers D, et al., Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. British Journal of Anaesthesia 2010; 105: 558-67.
46. Schaller SJ, Fink H,. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evidence 2013; 8: 57-67.
47. Sasaki N, Meyer MJ, Malviya SA, et al., Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes: a prospective study. Anesthesiology 2014; 121: 959-68.
48. Ledowski T, Falke L, Johnston F, et al., Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. European Journal of Anaesthesiology 2014; 31: 423-9.
49. Kotake Y, Ochiai R, Suzuki T, et al., Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesthesia and Analgesia 2013; 117: 345-51.
50. Cammu GV, Smet V, De Jongh K, Vandeput D,. A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine orsugammadex or after apparent spontaneous recovery. Anaesthesia and Intensive Care 2012; 40: 999-1006.
51. Della Rocca G, Pompei L, Pagan DE, et al., Reversal of rocuronium induced neuromuscular block with sugammadex orneostigmine: a large observational study. Acta Anaesthesiologica Scandinavica 2013; 57: 1138-45.
52. Ledowski T, Hillyard S, O'Dea B, et al., Introduction of sugammadex as standard reversal agent: impact on the incidence of residual neuromuscular blockade and postoperative patient outcome. Indian Journal of Anaesthesia 2013; 57: 46-51.
53. Naguib M, Brull SJ, Arkes HR,. Reasoning of an anomaly: residual block after sugammadex. Anesthesia and Analgesia 2013; 117: 297-300.
54. Van Gestel L, Cammu G,. Is the effect of sugammadex always rapid in onset? Acta anaesthesiologica Belgica 2013; 64: 41-7.
55. Dubois PE, Mulier JP,. A review of the interest of sugammadex for deep neuromuscular blockade management in Belgium. Acta Anaesthesiologica Belgica 2013; 64: 49-60.